2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1394

Clinical Characteristics of Sarcoid Arthropathy: A Population-Based Study
Abstract Number: 2256

Clinical Characteristics, Laboratory Findings and Nailfold Capillaroscopy Microscopy Patterns in a Monocentric Series of 123 Patients with Idiopathic Pernio
Abstract Number: 1562

Clinical Correlates, Outcomes and Predictors of Episcleritis and Scleritis Associated with Rheumatoid Arthritis
Abstract Number: 476

Clinical Disease Activity Measures Change Substantially and Irregularly over Time in Individual Rheumatoid Arthritis Patients Considered to be in Steady State
Abstract Number: 1986

Clinical Efficacy of Tocilizumab in Polymyalgia Rheumatica: An OPEN-Label Study.
Abstract Number: 773

Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA
Abstract Number: 2438

Clinical Examination of the Temporomandibular Joint; A Eurotmjoint Initiative
Abstract Number: 466

Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis
Abstract Number: 3066

Clinical Features and Treatments of Takayasu Arteritis Complicated with Ulcerative Colitis
Abstract Number: 2376

Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Abstract Number: 394

Clinical Features of Children with Silent Lupus Nephritis
Abstract Number: 154

Clinical Features of Fibromyalgia in Patients with Rheumatoid Arthritis Predict Lower Power Doppler Scores on Ultrasound
Abstract Number: 2379

Clinical Follow-up Predictors of Disease Pattern Change in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International and Retrospective Study
Abstract Number: 688

Clinical Improvements in Psoriasis and Psoriatic Arthritis with Surgical Weight Loss
Abstract Number: 765

Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].